Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Double or Triple Hit Lymphoma

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Double or Triple Hit Lymphoma
Conditions:   Diffuse Large B-Cell Lymphoma;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   High Grade B-Cell Lymphoma With MYC, BCL2 and BCL6 Rearrangements
Interventions:   Drug: Prednisone;   Drug: Prednisolone;   Drug: Methylprednisolone;   Biological: Rituximab;   Drug: Polatuzumab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride
Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 22, 2020 / by / in
Comments